Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

I-SPY 2 Helping To Normalize Adaptive Trial Designs

Executive Summary

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.

Advertisement

Related Content

AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
FDA Encourages Pediatric Master Protocols With Bayesian Approach
XBiotech Stands By Advanced Colorectal Cancer Phase III Study
I-SPY Graduates: Where Are They Now?
Sky's The Limit On Savings For New NIH-Funded Innovative Trials Center
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
Tissue-Agnostic Approach To Cancer Drug Development Takes A Hit
Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial
Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register